Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma Inc.

Athena Gold ( ($TSE:ATHA) ) has provided an update. Athena Gold Corporation, a company involved in the mining sector, has released its unaudited co...

Athena Gold Corporation Reports Increased Assets in Q3 2025

Athena Gold ( ($TSE:ATHA) ) has shared an announcement. Athena Gold Corporation announced a non-brokered private placement to raise up to CDN $2 mi...

Athena Gold Launches $2 Million Private Placement for Exploration Expansion

Athena Gold ( ($TSE:ATHA) ) has shared an update. Athena Gold Corporation has announced a significant expansion of its landholding at the Excelsior...

Athena Gold Expands Landholding at Excelsior Springs Project

An update from Athena Gold ( ($TSE:ATHA) ) is now available. Athena Gold Corporation announced significant exploration updates from its Excelsior S...

Market Cap	$15.42M	P/E Ratio	NaN
52W High	$6.79	52W Low	$2.20
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	52.4%
Overall Score	70	Value Score	60
Quality Score	--	Technical Score	81

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATHA	$4.61	+1.43%	28.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATHA	$4.61	+1.4%	28.37K
3
4
5
6

ATHA

ATHA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Athira Pharma Inc. Data in Excel

Get Athira Pharma Inc. Data in Excel